Reagents News and Research

RSS

ERS Genomics and Applied StemCell sign agreement on commercialization of CRISPR gene editing tools

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property (IP) co-owned by Dr. Emmanuelle Charpentier, today announced it has signed an agreement with Applied StemCell, Inc., a leading provider of stem cell, animal model, antibody discovery services and reagents.

17 Sep 2020

Computational model can help identify best allocation plans for distributing test kits

Getting accurate, timely information on COVID-19 cases is one of the major challenges facing policymakers as they make decisions about public health and the economy.

15 Sep 2020

Avacta to launch Affimer-based ELISA test for SARS-CoV-2 virus detection

Avacta Group plc, the developer of Affimer biotherapeutics and reagents, is pleased to announce that it will launch an ELISA laboratory test for the SARS-CoV-2 spike protein to support global research efforts into the coronavirus that causes COVID-19.

From Avacta Life Sciences Ltd. 8 Sep 2020

Moving towards a new age of personalized, cell-based interceptive medicine for Europe

Hundreds of innovators, research pioneers, clinicians, industry leaders and policy makers from all around Europe are united by a vision of how to revolutionize healthcare.

7 Sep 2020

Pooled saliva testing increases COVID-19 testing capacity

Now, a new study by researchers at Yale School of Medicine and published on the preprint server medRxiv in September 2020 shows that pooled saliva samples can save resources and increase testing capacity, making a significant difference in the management of the pandemic.

7 Sep 2020

Promega and Hitachi High-Tech launch Spectrum Compact CE System

Promega today launched its benchtop capillary electrophoresis (CE) instrument, the Spectrum Compact CE System, developed in collaboration with Hitachi High-Tech.

From Promega Corporation 3 Sep 2020

New Gyrolab AAVX Titer Kit launched to support the development cell and gene therapies

Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and a leading provider of peptide synthesizers and reagents, today announced the introduction of Gyrolab® AAVX Titer Kit for adeno-associated virus (AAV) vector titer determination in AAV vector manufacturing.

From Gyros Protein Technologies AB 3 Sep 2020

Avacta enters into manufacturing agreement with Abingdon Health for rapid SARS-CoV-2 antigen test

Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has entered into an agreement with Abingdon Health for the manufacture of Avacta’s saliva-based rapid SARS-CoV-2 antigen test as part of its ongoing expansion of manufacturing capacity.

From Avacta Life Sciences Ltd. 3 Sep 2020

NIH provides scale-up and manufacturing support for new COVID-19 testing technologies

The National Institutes of Health today announced $129.3 million in scale-up and manufacturing support for a new set of COVID-19 testing technologies as part of its Rapid Acceleration of Diagnostics (RADx) initiative.

2 Sep 2020

NIAID awards $17 million to establish the Centers for Research in Emerging Infectious Diseases

The National Institute of Allergy and Infectious Diseases, one of the National Institutes of Health, today announced that it has awarded 11 grants with a total first-year value of approximately $17 million to establish the Centers for Research in Emerging Infectious Diseases.

27 Aug 2020

Bio-Helix announces approved patent for ECL

Bio-Helix is pleased to be notified of the approved patent application for its proprietary enhanced chemiluminescent substrates (ECL).

24 Aug 2020

New COVID-19 pooling test detects asymptomatic carriers

A new peer-reviewed study published in Science Advances confirms the success of a new COVID-19 pooling test that identifies all positive subjects, including asymptomatic carriers, in a single round of testing.

21 Aug 2020

The Native Antigen Company announces custom contract service to develop influenza A and B antigens

The Native Antigen Company, one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the introduction of its custom contract service to rapidly develop antigen panels for influenza A and B viruses.

21 Aug 2020

Avacta expands multi-target collaboration with LG Chem Life Sciences

Avacta Group plc, the developer of Affimer biotherapeutics and reagents, is pleased to announce the expansion of its existing multi-target collaboration and development agreement with LG Chem Life Sciences (LG Chem), the life sciences division of the South Korean LG Group, to include new programs incorporating Avacta’s Affimer XT serum half-life extension system.

From Avacta Life Sciences Ltd. 21 Aug 2020

Absolute Antibody offers SARS-CoV-2 neutralizing antibodies derived from COVID-19 patients

Absolute Antibody Ltd. today announced the availability of SARS-CoV-2 neutralizing antibodies derived from individuals infected with COVID-19.

From Absolute Antibody Ltd 18 Aug 2020

FDA grants emergency use authorization to Yale's SalivaDirect COVID-19 diagnostic test

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) to Yale School of Public Health for its SalivaDirect COVID-19 diagnostic test, which uses a new method of processing saliva samples when testing for COVID-19 infection.

15 Aug 2020

Portable testing laboratory screens millions of bacteria in water samples

A suitcase-size portable testing laboratory could cut back the time and money spent on monitoring water quality in developing countries.

14 Aug 2020

New test allows rapid COVID-19 diagnosis

Researchers have developed a new test that can diagnose COVID-19 in just 20 minutes. The findings, published in the Journal of Medical Microbiology, show the rapid molecular test called N1-STOP-LAMP, is 100% accurate in diagnosing samples containing SARS-CoV-2 at high loads.

13 Aug 2020

Promega introduces new serological antibody test for COVID-19

Promega Corporation today announced the launch of its new serological antibody test for COVID-19 to detect the presence of antibodies against the SARS-CoV-2 virus.

From Promega Corporation 13 Aug 2020

Neil Bell appointed as Chief Development Officer of Avacta Life Sciences

Avacta Group plc, the developer of Affimer biotherapeutics and reagents, is pleased to announce the appointment of Neil Bell as Chief Development Officer of Avacta Life Sciences with immediate effect. Neil will be responsible for late stage pre-clinical and early clinical development of Avacta’s pipeline of pre|CISION pro-drugs and Affimer immunotherapies.

From Avacta Life Sciences Ltd. 13 Aug 2020